Court Opinion

ID: 4673425
Source: CourtListenerOpinion
Date Created: 2021-03-31 22:08:06.629043+00
Date Added: 2024-06-11T08:03:13.763768
License: Public Domain

2021 IL App (1st) 200527

                                                                            FIFTH DIVISION
                                                                            MARCH 31, 2021

No. 1-20-0527

CASTLERIGG MASTER INVESTMENTS, LTD., )                       Appeal from the
                                     )                       Circuit Court of
     Plaintiff-Appellant,            )                       Cook County.
                                     )
v.                                   )                       No. 19 L 11309
                                     )
ABBVIE, INC. and RICHARD GONZALEZ,   )                       Honorable
                                     )                       Margaret A. Brennan,
     Defendants-Appellees.           )                       Judge Presiding.

       JUSTICE CUNNINGHAM delivered the judgment of the court, with opinion.
       Justices Hoffman and Rochford concurred in the judgment and opinion.

                                           OPINION

¶1     The plaintiff-appellant, Castlerigg Master Investments, Ltd. (Castlerigg), appeals from the

circuit court of Cook County’s dismissal of its complaint against the defendants-appellees,

AbbVie, Inc. (AbbVie) and Richard Gonzalez, for failure to state a claim. For the following

reasons, we affirm the judgment of the circuit court of Cook County.

¶2                                      BACKGROUND

¶3     Castlerigg is an investment fund based in the British Virgin Islands with its principal place

of business in New York, New York. AbbVie is a Delaware-incorporated pharmaceutical company

with its principal place of business in North Chicago, Illinois. Mr. Gonzalez is AbbVie’s chief

executive officer (CEO) and chairman of the board.
1-20-0527

¶4        On June 20, 2014, AbbVie announced that it had approached another pharmaceutical

company, Shire PLC (Shire), with an acquisition proposal. 1 Shire is organized under the laws of

the island of Jersey, a self-governing dependency of the United Kingdom, and headquartered in

Ireland. AbbVie disclosed that as part of its acquisition proposal with Shire, AbbVie would

reincorporate as a foreign company outside of the United States and create a tax inversion, which

would significantly reduce the amount it paid in taxes in the United States.

¶5        On July 18, 2014, AbbVie and Shire announced they had reached agreed terms and signed

a merger agreement. The merger agreement provided that AbbVie would merge with Shire, with

AbbVie as the surviving entity reincorporating in Jersey. The merger agreement projected a new,

lower tax rate for the newly merged entity as a consequence of reincorporation under the laws of

Jersey.

¶6        That same day, Mr. Gonzalez held an investor conference call to discuss the merger

agreement. During the conference call, investment analysts asked Mr. Gonzalez about the

emerging political debate in the United States surrounding tax inversions and the risk of United

States government action to eliminate or restrict tax inversion benefits. Mr. Gonzalez answered

that AbbVie had “studied this transaction very, very carefully” and believed it was “highly

executable.” He stated that the tax inversion was an additional benefit but “not the primary

rationale” for the merger agreement.

¶7        On September 22, 2014, while the merger agreement was pending, the United States

Treasury Department announced new federal tax regulations that would limit certain benefits of

tax inversions and diminish the ability of inverted companies to pay a lower tax rate to the United

States (the treasury notice).

          1
           Shire is not a party to this appeal.

                                                  -2-
1-20-0527

¶8      On September 29, 2014, Mr. Gonzalez issued a letter to all Shire employees, which AbbVie

publicized to investors and filed with the United States Securities and Exchange Commission (the

Shire letter). The Shire letter stated that AbbVie was still moving forward with the merger

agreement and that Mr. Gonzalez was “more energized than ever” and “confident” about it.

AbbVie also published a letter to its own employees stating that it was aiming for a fourth-quarter

close of the merger agreement (the AbbVie letter).

¶9      As of September 29, 2014, Castlerigg held 114,457 Shire American depository receipts

(ADRs) 2, worth more than $29.8 million based on the closing price of $260.67 that day. 3

According to Castlerigg, the conference call, as well as the Shire and AbbVie letters, induced it to

maintain its Shire ADRs based on the belief that the merger agreement would close later that year.

¶ 10    On October 14, 2014, AbbVie announced that it was reconsidering the merger agreement,

due, in part, to the September 22, 2014, treasury notice. On October 15, 2014, AbbVie confirmed

that it was terminating the merger agreement. AbbVie’s announcement stated:

                         “Although the strategic rationale of combining our two companies remains

                 strong, the agreed upon valuation is no longer supported as a result of the changes

                 to the tax rules and we did not believe it was in the best interests of our stockholders

                 to proceed.”

Following AbbVie’s announcement that it was not moving forward with the merger agreement,

Shire’s ADRs fell 30% in value in one day.

¶ 11        On October 11, 2019, Castlerigg filed a complaint against AbbVie and Mr. Gonzalez in

        2
         ADRs are negotiable certificates representing ownership in publicly traded foreign corporations.
Cohan v. Citicorp, 266 Ill. App. 3d 626, 627 (1993).
       3
         The parties do not indicate when Castlerigg acquired its Shire ADRs; nor is that information
apparent in the record on appeal.

                                                  -3-
1-20-0527

the circuit court of Cook County. The complaint alleged that, as a merger arbitrage investor,

Castlerigg buys and holds stocks based on the probability of an acquisition closing, which requires

“careful monitoring” and evaluation to determine if a proposed acquisition will close. Regarding

the merger agreement at issue in this case, Castlerigg’s complaint alleged that AbbVie’s and Mr.

Gonzalez’s “assurances on September 29, 2014 induced [Castlerigg] to maintain its judgment that

the [merger agreement] would close and hold Shire ADRs worth approximately $30 million.”

Castlerigg alleged that AbbVie made fraudulent misrepresentations in the Shire and AbbVie letters

regarding the status of the merger agreement. Specifically, the complaint stated:

                      “As the CEO, Board Chairman and leader of AbbVie’s effort to acquire

               Shire, [Mr.] Gonzalez had special knowledge of the probability that the merger

               would not close in light of the September 22, 2014 tax regulation changes. AbbVie

               abandoned the Shire transaction just two weeks after [Mr.] Gonzalez’s statements.

               On information and belief, [Mr.] Gonzalez’s statements lacked factual basis, and

               [Mr.] Gonzalez knew facts about AbbVie’s internal reaction to the tax regulation

               changes that were incompatible with his statements. On information and belief,

               [Mr.] Gonzalez and AbbVie made the statements with reckless disregard for their

               truth or falsity, knowing that Shire investors such as [Castlerigg], having no reason

               to believe [AbbVie’s and Mr. Gonzalez’s] statements were untrue or misleading,

               scrutinized and relied on their statements.”

¶ 12   Castlerigg’s complaint further alleged that “it would neither have continued to hold its

positions in Shire, nor would [it] have maintained its judgment the transaction would close, if

[Castlerigg] knew that AbbVie was then evaluating whether to abandon the Shire acquisition as a

result of the recently announced restrictions on tax inversions.” Castlerigg’s complaint concluded

                                               -4-
1-20-0527

by stating that because it held onto its Shire ADRs based on AbbVie’s and Mr. Gonzalez’s

misrepresentations, it was injured when the value of Shire ADRs dropped by 30% following

AbbVie’s announcement that it was terminating the merger agreement. The complaint sought

compensatory damages, punitive damages, and interest all “in an amount to be determined at trial.”

¶ 13      AbbVie and Mr. Gonzalez filed a combined motion to dismiss Castlerigg’s complaint

pursuant to section 2-619.1 of the Code of Civil Procedure (Code) (735 ILC 5/2-619.1) (West

2018)). The motion to dismiss argued that the trial court should dismiss Castlerigg’s complaint

pursuant to section 2-615 of the Code (id. § 2-615) because the complaint did not adequately plead

a fraud claim, and because the complaint was time barred by the statute of limitations, pursuant to

section 2-619 of the Code (id. § 2-619). AbbVie and Mr. Gonzalez argued that Castlerigg had

failed to plead a fraud claim because Illinois does not recognize “holder claims,” 4 such as that

alleged in Castlerigg’s complaint. They argued that the Illinois Securities Law of 1953 (Securities

Law) (815 ILCS 5/1 et seq. (West 2018)) protects investors from fraud regarding the sale or

purchase of securities, but not regarding the holding of securities. Citing Dloogatch v. Brincat,

396 Ill. App. 3d 842, 847 (2009), AbbVie and Mr. Gonzalez stated in their motion: “Castlerigg

pursues its holder claims under a common law cause of action for fraud. But this attempt to end-

run the Securities Law fails because Illinois courts have never recognized Castlerigg’s purported

claim.” AbbVie and Mr. Gonzalez asked the trial court to dismiss Castlerigg’s complaint for failure

to state a claim.

¶ 14      Following a hearing on AbbVie and Mr. Gonzalez’s motion to dismiss, the trial court

stated:

          4
         A “holder claim” occurs when the plaintiff is the holder of certain corporate securities, the value
of which the corporation fraudulently inflates; when the fraud is discovered, the price of the stock drops
precipitously, causing injury to the stockholder. See Small v. Fritz Cos., 65 P.3d 1255, 1256-57 (Cal. 2003).

                                                    -5-
1-20-0527

                       “Okay. I believe Dlooglatch does control here and for those reasons I think

               what you have pled is a holder claim, and the case is dismissed.

                       But in an effort to make sure that there’s no ambiguity or if this is reviewed

               at some point in time by a higher court, I also note that there’s no way you can take

               this outside of kind of the Securities Law as much as you’re trying to do so and the

               three[-]year Statute of Limitations would also control.

                       So for both reasons, although I find that no cause of action for a holder claim

               can be pled in Illinois, I think Dlooglatch is very clear on that, so it is dismissed.

               But were that should be look[ed] at that this is just common[-]law fraud, I think the

               securities element of this is such that the three[-]year Statute of Limitations would

               control and the case is dismissed.”

¶ 15   The trial court therefore dismissed Castlerigg’s complaint with prejudice. This appeal

followed.

¶ 16                                        ANALYSIS

¶ 17   We note that we have jurisdiction to consider this matter, as Castlerigg filed a timely notice

of appeal. See Ill. S. Ct. R. 301 (eff. Feb. 1, 1994); R. 303 (eff. July 1, 2017).

¶ 18   Castlerigg presents the following issue: whether the trial court erred in dismissing its

complaint. Castlerigg argues the trial court erred in holding that Illinois does not recognize holder

claims. Further, Castlerigg claims that it did adequately plead the elements of a common-law fraud

claim. Castlerigg also argues that the trial court erred in dismissing its complaint on the alternative

grounds of statute of limitations.

¶ 19   “A motion to dismiss brought pursuant to section 2-615 of the Code challenges the legal

sufficiency of a complaint by alleging defects on its face.” Alpha School Bus Co. v. Wagner, 391

                                                 -6-
1-20-0527

Ill. App. 3d 722, 735 (2009). While a plaintiff is not required to prove his case at the pleading

stage, he must allege sufficient facts to state all the elements that are necessary to sustain his cause

of action. Visvardis v. Ferleger, P.C., 375 Ill. App. 3d 719, 724 (2007). A trial court should dismiss

a complaint under section 2-615 only if it is readily apparent from the pleadings that there is no

possible set of facts that would entitle the plaintiff to the requested relief. Quinn v. Board of

Education of the City of Chicago, 2018 IL App (1st) 170834, ¶ 57. “The question for the court is

whether the allegations of the complaint, when construed in the light most favorable to the

plaintiffs, are sufficient to establish the cause of action.” Id. We review de novo the trial court’s

dismissal of a complaint pursuant to section 2-615. Wagner, 391 Ill. App. 3d at 735.

¶ 20    The elements of common-law fraud are (1) a false statement of material fact by the

defendant, (2) who knew that the statement was false (3) and intended to induce the plaintiff to act

in reliance upon the statement, (4) the plaintiff reasonably relied upon the truth of the statement,

and (5) the plaintiff suffered damage as a result of action in reliance upon the statement. Feis

Equities, LLC v. Sompo International Holdings, Ltd., 2020 IL App (1st) 191072, ¶ 51. It is well

established that fraud-based claims demand a higher standard when it comes to pleadings, as there

must be specific allegations of facts to support the claim. Merrilees v. Merrilees, 2013 IL App

(1st) 121897, ¶ 15.

¶ 21    Castlerigg argues that its complaint adequately pled a holder claim, which should be

recognized in Illinois, as well as a common-law fraud claim. We are guided in our analysis by

Dloogatch, 396 Ill. App. 3d 842, which has analogous facts. In Dloogatch, investors alleged that

a finance company’s auditor committed fraud by using fraudulent financial reports to induce them

to retain stock. Id. at 843. This court affirmed the trial court’s dismissal of the complaint for failure

to state a claim, specifically for failing to adequately plead reliance and damages. Id. at 854. In so

                                                  -7-
1-20-0527

ruling, we noted that Illinois has yet to recognize holder claims, stating: “No court in Illinois has,

as of yet, decided whether holders of securities even have a cognizable claim based on common[-

]law fraud.” Id. at 847. Ultimately, we held that, “whether or not this court decides to recognize

‘holder claims,’ ” the plaintiffs in Dloogatch, had failed to plead reliance without more than

“simply a conclusory statement that gives no insight into facts that plaintiffs would ever be able to

prove supporting that claim.” Id. at 850. We further held that the plaintiffs in that case had failed

to adequately plead damages, and in so ruling, we noted the speculation, windfalls, and general

difficulties associated with calculating damages in holder claims. Id. at 850-53.

¶ 22   Likewise, in the instant case, Castlerigg’s complaint demonstrates the problems with holder

claims related to damages among other shortcomings and similarly fails to adequately plead a

common-law fraud claim. The elements of common-law fraud in dispute here are reliance and

damages. In order to adequately plead reliance, Castlerigg needed to detail its reliance upon the

defendant’s actions and words with “sufficient specificity and particularity.” Id. at 850. However,

Castlerigg merely alleged that AbbVie’s and Mr. Gonzalez’s misrepresentations about the treasury

notice induced it to hold onto its Shire ADRs. Castlerigg did not provide any more detail, such as

how many ADRs would have been sold and when the sale would have taken place. Without such

basic facts, it is nearly impossible to prove reliance. See id. Indeed, this analysis demonstrates

precisely why holder claims are problematic. See Small v. Fritz Cos., 65 P.3d 1255, 1266 (Cal.

2003) (“Plaintiffs who cannot plead with sufficient specificity to show a bona fide claim of actual

reliance do not stand out from the mass of stockholders who rely on the market.”). We accordingly

find that Castlerigg failed to adequately plead the element of reliance.

¶ 23   Further, Castlerigg failed to adequately allege the element of damages. While plaintiffs are

generally not required to calculate damages, Castlerigg did not even provide a method for

                                                -8-
1-20-0527

calculating the damages it sought. In light of the nature of this claim, this is an important factor to

consider. Castlerigg’s complaint simply sought compensatory damages, punitive damages, and

interest all “in an amount to be determined at trial.” Yet, damages is an essential element of fraud.

City of Chicago v. Michigan Beach Housing Cooperative, 297 Ill. App. 3d 317, 323 (1998).

Absolute certainty about the amount of damages is not necessary, but damages may not be

predicated upon mere speculation, and the plaintiff must show a basis for computing damages with

a fair degree of probability. Id. Thus, Castlerigg’s blanket statement in saying it was damaged by

AbbVie’s and Mr. Gonzalez’s misrepresentations and requesting that the trial court determine the

amount of damages was insufficient to adequately meet the pleading requirement for the element

of damages.

¶ 24    Notably, Castlerigg likely did not calculate its damages because of the speculative and

troublesome nature of calculating damages for holder claims. Had AbbVie announced that it was

reconsidering the merger agreement with Shire earlier, as Castlerigg avers it should have, Shire’s

ADRs would likely still have fallen in value immediately following the announcement. Whether

they would have fallen the same 30% or a different amount is entirely speculative. It could be said

that Castlerigg’s loss resulted from the revelation of the truth rather than the alleged fraud. See

Dloogatch, 396 Ill. App. 3d at 851-52 (plaintiffs’ loss derives not from the fraud per se but from

the disclosure of the misrepresentations and the subsequent correction in the market price of the

stock). Further, it should also be noted that some methods for calculating damages in holder claims

present the potential for a windfall to plaintiffs who profit from fraud-inflated stocks. Id. at 853. It

is interesting to note that it is Shire’s ADRs that Castlerigg was holding at the time of the alleged

fraud. Unlike true holder cases, Shire is an unimplicated third party with regard to the alleged

fraud, yet it is the value of its ADRs which is at the center of Castlerigg’s alleged damages. This

                                                 -9-
1-20-0527

underscores another difficulty in establishing the propriety of the initial valuation, which in turn

would bear upon reliance and damages.

¶ 25    In sum, Castlerigg failed to adequately plead reliance and damages and therefore failed to

plead a claim for fraud. Accordingly, we affirm the trial court’s judgment dismissing Castlerigg’s

complaint on the basis that it failed to state a claim. Consequently, we need not address the trial

court’s alternative grounds for dismissing the complaint, i.e., that the complaint is time-barred by

the statute of limitations.

¶ 26                                     CONCLUSION

¶ 27    For the foregoing reasons, we affirm the judgment of the circuit court of Cook County.

¶ 28    Affirmed.

                                               - 10 -
1-20-0527

                                  No. 1-20-0527

Cite as:                 Castlerigg Master Investments, Ltd. v. Abbvie, Inc., 2021 IL App
                         (1st) 200527

Decision Under Review:   Appeal from the Circuit Court of Cook County, No. 19-L-11309;
                         the Hon. Margaret A. Brennan, Judge, presiding.

Attorneys                Michael D. Smith, Law Office of Michael D. Smith, P.C., of
for                      Chicago, and David J. Goldsmith, of Labaton Sucharow LLP, of
Appellant:               New York, New York, for appellant.

Attorneys                Tarek Ismail, Alan Littmann, Andrew Rima, and Betsy
for                      Farrington, of Goldman Ismail Tomaselli Brennan & Baum LLP,
Appellee:                and James F. Hurst, Andrew A. Kassof, Gabor Balassa, and
                         Whitney L. Becker, of Kirkland & Ellis LLP, both of Chicago,
                         for appellees.

                                       - 11 -